Rosetta gets Notice of Allowance on prostate cancer diagnostic

|About: Rosetta Genomics Ltd. (ROSG)|By:, SA News Editor

Rosetta Genomics (ROSG +8.7%) receives a Notice of Allowance from the USPTO for its patent application entitled "Compositions and Methods for Prognosis and Treatment of Prostate Cancer." The patent (No. 13/390,995) claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer.